Activation of the PI3K-Akt pathway is commonly observed in NPC patients, therefore, we hypothesized that the combination of ribociclib and the alpha-isoform specific PI3K inhibitor alpelisib may be synergistic. The gene discussed is PIK3CA; the disease is nasopharyngeal carcinoma.